Meropenem Kabi (Meropenem Trihydrate)

Meropenem, the active ingredient in Meropenem Kabi, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It provides broad‑spectrum coverage against Gram‑negative and Gram‑positive bacteria and is employed in the treatment of severe infections such as complicated intra‑abdominal infections, hospital‑acquired pneumonia, and bacterial meningitis in hospitalized adults.

GNH USA supplies Meropenem Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global healthcare institutions.

Meropenem is a carbapenem antibiotic used to treat serious bacterial infections affecting multiple organ systems.

Complicated intra‑abdominal infections: provides broad‑spectrum bacterial eradication in patients with intra‑abdominal sepsis. Complicated urinary tract infections: eliminates resistant Gram‑negative uropathogens in complicated cases. Hospital‑acquired pneumonia: offers effective coverage against multidrug‑resistant respiratory pathogens. Ventilator‑associated pneumonia: treats ventilator‑related infections with high bacterial load. Meningitis: penetrates the cerebrospinal fluid to combat susceptible bacterial meningitis agents. Severe sepsis and septic shock: delivers rapid bactericidal activity in critically ill patients.

Adverse reactions may occur with meropenem therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhea: may be watery and self‑limiting. - Headache: transient and usually resolves without intervention. - Rash: mild erythematous skin eruption. - Elevated liver enzymes: transient increase in hepatic transaminases. - Injection site pain: local discomfort during IV administration.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or pre‑existing CNS disorders. - Anaphylaxis: severe hypersensitivity reaction requiring immediate medical attention. - Clostridioides difficile colitis: antibiotic‑associated colitis presenting with severe diarrhea. - Severe neutropenia: marked reduction in neutrophil count increasing infection risk. - Thrombocytopenia: low platelet count potentially leading to bleeding. - Renal toxicity: acute kidney injury in susceptible individuals.

Key safety considerations should be observed when using meropenem.

Renal function: adjust dosing in patients with impaired renal clearance. Allergy history: verify no prior hypersensitivity to carbapenems or β‑lactams. Seizure risk: monitor neurologic status, especially in patients with CNS disorders. Pregnancy and lactation: use only if the potential benefit justifies the potential risk. Concomitant antibiotics: assess for additive toxicity when combined with other nephrotoxic agents. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Valproic acid: meropenem reduces serum valproate levels, risking seizure breakthrough. - Other carbapenems: concurrent use may increase toxicity without added benefit.

Moderate Interactions (Monitor Closely): - Aminoglycosides: combined nephrotoxic potential warrants renal function monitoring. - Warfarin: may enhance anticoagulant effect; monitor INR closely. - Oral contraceptives: possible reduction in efficacy; advise alternative contraception.